206 related articles for article (PubMed ID: 37325665)
1. Editorial: Predictive short/long-term efficacy biomarkers and resistance mechanisms of CAR-T immunotherapy treatment.
Cheng J; Jin J; Chen L
Front Immunol; 2023; 14():1206441. PubMed ID: 37325665
[No Abstract] [Full Text] [Related]
2. Predictive and therapeutic biomarkers in chimeric antigen receptor T-cell therapy: A clinical perspective.
Mirzaei HR; Mirzaei H; Namdar A; Rahmati M; Till BG; Hadjati J
J Cell Physiol; 2019 May; 234(5):5827-5841. PubMed ID: 30317583
[TBL] [Abstract][Full Text] [Related]
3. Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas.
Xu H; Li N; Wang G; Cao Y
Front Immunol; 2023; 14():1110028. PubMed ID: 37051246
[TBL] [Abstract][Full Text] [Related]
4. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
Miao L; Zhang Z; Ren Z; Tang F; Li Y
Front Immunol; 2021; 12():687822. PubMed ID: 34093592
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
6. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M
J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.
Mao R; Hussein MS; He Y
Expert Rev Mol Med; 2022 Jan; 24():e7. PubMed ID: 35086597
[TBL] [Abstract][Full Text] [Related]
8. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor (CAR) T-cell Therapy: A New Genetically Engineered Method of Immunotherapy for Cancer.
Singh AK; Malviya R; Singh A; Sundram S; Mishra S
Curr Cancer Drug Targets; 2023; 23(3):199-210. PubMed ID: 36173082
[TBL] [Abstract][Full Text] [Related]
10. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
11. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
12. Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: from basic to practice.
Wudhikarn K; Park JH
Leuk Lymphoma; 2020 Oct; 61(10):2324-2334. PubMed ID: 32522059
[TBL] [Abstract][Full Text] [Related]
13. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
Ti D; Niu Y; Wu Z; Fu X; Han W
Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
Han C; Kwon BS
Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
[TBL] [Abstract][Full Text] [Related]
15. First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G.
Anna F; Bole-Richard E; LeMaoult J; Escande M; Lecomte M; Certoux JM; Souque P; Garnache F; Adotevi O; Langlade-Demoyen P; Loustau M; Caumartin J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737343
[TBL] [Abstract][Full Text] [Related]
16. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
[TBL] [Abstract][Full Text] [Related]
17. Opportunities and obstacles for the melanoma immunotherapy using T cell and chimeric antigen receptor T (CAR-T) applications: a literature review.
Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori H; Mansoori Y; Salahi A; Nikfar G; Tavassoli A; Behmard E; Moravej A; Ghasemian A
Mol Biol Rep; 2022 Nov; 49(11):10627-10633. PubMed ID: 35715610
[TBL] [Abstract][Full Text] [Related]
18. INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies-Established Findings and Future Priorities.
Ligon JA; Ramakrishna S; Ceppi F; Calkoen FGJ; Diorio C; Davis KL; Jacoby E; Gottschalk S; Schultz LM; Capitini CM
Transplant Cell Ther; 2024 Feb; 30(2):155-170. PubMed ID: 37863355
[TBL] [Abstract][Full Text] [Related]
19. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
Zhang P; Zhang Y; Ji N
Front Immunol; 2022; 13():927132. PubMed ID: 35874698
[TBL] [Abstract][Full Text] [Related]
20. Current perspectives on resistance to chimeric antigen receptor T-cell therapy and strategies to improve efficacy in B-cell lymphoma.
Ong SY; Chen Y; Tan MSY; Ho AYL; Hwang WYK; Lim FLWI
Eur J Haematol; 2024 Feb; 112(2):144-152. PubMed ID: 36987995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
